Striatal Indirect Pathway Medium Spiny Neurons (D2 Msns) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Striatal Indirect Pathway Medium Spiny Neurons (D2-MSNs), also known as "No-Go" neurons, are essential for movement suppression and action inhibition. These neurons express dopamine D2 receptors and form the indirect pathway that prevents unwanted movements.
| Property | Value |
|---|---|
| Category | Cell Types |
| Brain Region | Basal Ganglia, Striatum |
| Neurotransmitter | GABA (inhibitory) |
| Cell Type | Medium Spiny Neuron (MSN) |
| Dopamine Receptor | D2R (Drd2) |
| Associated Diseases | Parkinson's Disease, Huntington's Disease, Schizophrenia |
The indirect pathway suppresses movement through the following circuit:
Cortex ( glutamatergic) → D2-MSNs → GPe (inhibition) → STN (disinhibition) → GPi/SNr (excitation) → Thalamus (inhibition) → Cortex (suppression)
Dopamine → D2R → Gi/o → AC inhibition → cAMP ↓ → PKA inhibition
↓
Reduced NMDA/AMPA signaling
↓
Decreased neuronal excitability
| Approach | Target | Status |
|---|---|---|
| D2 agonists | Indirect pathway inhibition | Approved for PD |
| A2A antagonists | D2-MSN disinhibition | Clinical trials for PD |
| PDE10A inhibitors | cAMP modulation | Clinical trials |
| Deep brain stimulation | GPi/SNr output modulation | Approved for PD/HD |
| Antisense oligonucleotides | mHTT silencing | Clinical trials for HD |
| Feature | Direct (D1-MSNs) | Indirect (D2-MSNs) |
|---|---|---|
| Effect on movement | Facilitate ("Go") | Suppress ("No-Go") |
| Dopamine effect | Excitatory | Inhibitory |
| Output target | GPi/SNr | GPe |
| Neuropeptides | Substance P, Dynorphin | Enkephalin |
| Clinical correlation | HD early loss | PD hyperactivity |
The study of Striatal Indirect Pathway Medium Spiny Neurons (D2 Msns) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990.
[2] Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron. 2008.
[3] Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989.
[4] Raymond LA, André VM, Cepeda C, et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic activity and neuronal excitability. Philos Trans R Soc B. 2011.
[5] Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci. 2004.
[6] Surmeier DJ, Plotkin J, Shen W. Dopamine and synaptic plasticity in basal ganglia circuits. Neural Plast. 2009.
[7] Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014.
[8] Freeze BS, Kravitz AV, Hammack N, Berke JD. Optogenetic manipulation of neural activity in freely moving rodents. Methods. 2011.